Shanghai Sinobioway Sunterra Biotechnology
Shanghai Sinobioway Sunterra Biotechnology specializes in advanced biotechnology, particularly in adoptive cellular therapies aimed at treating solid tumor malignancies. Established through a collaboration between Sinobioway Group, Sunterra Capital, and F1 Oncology, the company is dedicated to developing innovative CAB-CAR-T therapies. To facilitate its research and development efforts, SSSB operates Good Manufacturing Practice (GMP) cell processing facilities in Shanghai, which support clinical research in partnership with leading academic institutions.
1 past transactions
EXUMA Biotech
Venture Round in 2018
EXUMA Biotech is a clinical-stage biotechnology company that develops CAR-T cell therapies for solid tumors. It focuses on enabling the immune system to attack solid malignancies, including renal cell carcinoma, soft tissue sarcoma, and gastric cancer. Founded in 2015, the company is based in Florida and maintains operations in California, the Cayman Islands, and China, with a strategic partnership with Shanghai PerHum Therapeutics Co., Ltd.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.